Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
dc.contributor.author | Hochmair, M. J. | |
dc.contributor.author | Reinmuth, N. | |
dc.contributor.author | Goldman, J. W. | |
dc.contributor.author | Garassino, M. C. | |
dc.contributor.author | Chen, Y. | |
dc.contributor.author | Hotta, K. | |
dc.contributor.author | Poltoratskiy, A. | |
dc.contributor.author | Trukhin, D. | |
dc.contributor.author | Ji, J. H. | |
dc.contributor.author | ÖZGÜROĞLU, MUSTAFA | |
dc.contributor.author | Statsenko, G. | |
dc.contributor.author | Voitko, O. | |
dc.contributor.author | Conev, N. V. | |
dc.contributor.author | Bondarenko, I. | |
dc.contributor.author | Mann, H. | |
dc.contributor.author | Xie, M. | |
dc.contributor.author | Shrestha, Y. | |
dc.contributor.author | Chugh, P. | |
dc.contributor.author | Dalvi, T. | |
dc.contributor.author | Paz-Ares, L. | |
dc.date.accessioned | 2022-07-04T14:18:09Z | |
dc.date.available | 2022-07-04T14:18:09Z | |
dc.identifier.citation | Reinmuth N., Goldman J. W. , Garassino M. C. , Chen Y., Hotta K., Poltoratskiy A., Trukhin D., Hochmair M. J. , Ji J. H. , ÖZGÜROĞLU M., et al., "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study", ANNALS OF ONCOLOGY, cilt.33, 2022 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.other | av_71cfff8b-3e6b-408e-8d83-aba24c619767 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/183268 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/71cfff8b-3e6b-408e-8d83-aba24c619767/file | |
dc.identifier.uri | https://doi.org/10.1016/j.annonc.2022.02.172 | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Oncology | |
dc.subject | Health Sciences | |
dc.subject | Tıp | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.title | Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study | |
dc.type | Makale | |
dc.relation.journal | ANNALS OF ONCOLOGY | |
dc.contributor.department | Asklepios Lung Clin , , | |
dc.identifier.volume | 33 | |
dc.contributor.firstauthorID | 3407320 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Makale [2276]